Join us on Sunday, September 12^th for this CME/MOC-accredited live webinar
9:15 PM – 10:15 PM MDT / 11:15 PM – 12:15 AM ET (ends next day on 13 Sep at 12:15 AM ET)

There is no fee to participate in this virtual event. Registration for this program is independent of registration for 2021 World Conference on Lung Cancer.


This activity is supported by an educational grant from Genentech, a member of the Roche Group.

This program was approved by the IASLC 2021 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2021 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

Sunday, September 12, 2021
9:15 PM – 10:15 PM MDT / 11:15 PM – 12:15 AM ET (ends next day on 13 Sep at 12:15 AM ET)
Live CME/MOC webinar

There is no fee to participate in this virtual event. Registration for this program is independent of registration for 2021 World Conference on Lung Cancer.

Topics to Be Discussed

• MODULE 1: Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC)
• MODULE 2: Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC
• MODULE 3: Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess the anticipated benefits, risks and long-term outcomes associated with the use of adjuvant and neoadjuvant therapy in the management of Stage IB-IIIA non-small cell lung cancer (NSCLC), and consider this information when counseling patients regarding current therapeutic recommendations.
• Analyze the biologic basis for the investigation of immune checkpoint inhibitors for patients with nonmetastatic NSCLC, and evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibodies.
• Appreciate emerging Phase III findings with the use of an anti-PD-L1 antibody after the completion of chemotherapy and surgery for patients with resectable NSCLC, and consider the potential effect of this information on current and future clinical practice.
• Evaluate the clinical relevance of the various genomic abnormalities found in patients with localized NSCLC, and appreciate available and emerging data attempting to validate the efficacy of targeted therapy in these individuals
• Recall the design of ongoing clinical trials evaluating immune checkpoint inhibitor therapy for patients with localized NSCLC, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Pass has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Garon — Consulting Agreements: ABL Bio, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Dracen Pharmaceuticals, Eisai Inc, EMD Serono Inc, GlaxoSmithKline, Merck, Natera Inc, Novartis, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Shionogi Inc, Xilio Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis. Dr Wakelee — Advisory Board (Compensated): AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Helsinn Healthcare SA, Janssen Biotech Inc, Mirati Therapeutics, Xcovery; Advisory Board (Not Compensated): Cellworks, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Research Funding to Institution: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Novartis, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Xcovery.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from Genentech, a member of the Roche Group.